Since pro-inflammatory mediators as tumor necrosis factor-α (TNFα) or Interleukin-1β (IL1β) are elevated in rheumatoid arthritis patients and trigger atherogenesis [9], the design of new drugs is focusing on the reduction of these inflammatory mediators. Here, IL1B is linked to rheumatoid arthritis.